In HNSCC, a potent and selective TRK kinase inhibitor, AZ-64 that targets TRKB, has been shown to inhibit tumor proliferation and migration, as well as overcome chemotherapy resistance in vitro (Yilmaz et al., 2010). This evidence concerns the gene NTRK2 and neoplasm.